Methylene Blue for Prevention of Perioperative Neurocognitive Disorders: Mechanisms and Recent Clinical Evidence (2026)

Peer-Reviewed Study · Wu Y, Wang J, Wan X · May 22, 2026

Wu Y et al., 2026-05-22: 2026 narrative review of methylene blue for perioperative neurocognitive disorders, assembling the mechanistic case and the randomised trial evidence in elderly surgical patients.

Currently, no pharmacological agent is universally accepted for PND prevention.

abstract

Wu Y et al., 2026-05-22: 2026 narrative review of methylene blue for perioperative neurocognitive disorders, assembling the mechanistic case and the randomised trial evidence in elderly surgical patients. Study type: narrative review (secondary). N/A. Country: not stated in abstract. No dose. Funders/conflicts: not stated in abstract. Useful as the current summary of the one area where randomised human cognitive outcomes with methylene blue exist outside psychiatry (postoperative delirium/cognitive dysfunction). Also filed as MTC-030 (claims C4, C8). Study type: review.